Abstract
BACKGROUND: Oral corticosteroids (OCS) associate with increased risk of cardiovascular disease (CVD). However, it is not clear whether use of high-dose inhaled corticosteroids (ICS) also links to increased CVD risk in asthma patients
AIM: Using Swedish data from the NORdic Dataset for aSThmA Research (NORDSTAR) cohort we examined whether current high-dose ICS exposure is associated with CVD
METHODS: This was an observational cohort study including asthma patients ≥18 years between 2009-19. A Cox regression model was used to examine the association between current ICS exposure (daily µg budesonide equivalent as a time-dependent predictor) and incident CVD using ICS-free patients as the reference group. Covariates included age, sex, and OCS dose
RESULTS: At study enrollment, 468,940 asthma patients were included. Overall, 62,971 developed CVD. A dose-response relationship was identified between overall CVD risk and high-dose ICS: Hazard ratio (HR) 1.20 (95%CI 1.17-1.24) for daily ICS dose 800-1599 µg increasing to HR 1.63 (95%CI 1.53-1.74) with >2400µg. Likewise, the risk of several CVD subtypes were associated with high-dose ICS (800-1599 µg): ischemic heart disease HR 1.21 (95%CI 1.13-1.3); atrial fibrillation HR 1.34 (95%CI 1.25-1.43) and heart failure HR 1.53 (95%CI 1.43-1.63). HRs increased further for ICS >1600 and >2400 µg daily. No increase in risk was found with ICS doses below 800 µg daily
CONCLUSION: We identified a dose-dependent risk of current high-dose ICS use on CVD onset. This highlights the importance of assessing CVD risk in patients with severe asthma. Further studies exploring this association are warranted.
AIM: Using Swedish data from the NORdic Dataset for aSThmA Research (NORDSTAR) cohort we examined whether current high-dose ICS exposure is associated with CVD
METHODS: This was an observational cohort study including asthma patients ≥18 years between 2009-19. A Cox regression model was used to examine the association between current ICS exposure (daily µg budesonide equivalent as a time-dependent predictor) and incident CVD using ICS-free patients as the reference group. Covariates included age, sex, and OCS dose
RESULTS: At study enrollment, 468,940 asthma patients were included. Overall, 62,971 developed CVD. A dose-response relationship was identified between overall CVD risk and high-dose ICS: Hazard ratio (HR) 1.20 (95%CI 1.17-1.24) for daily ICS dose 800-1599 µg increasing to HR 1.63 (95%CI 1.53-1.74) with >2400µg. Likewise, the risk of several CVD subtypes were associated with high-dose ICS (800-1599 µg): ischemic heart disease HR 1.21 (95%CI 1.13-1.3); atrial fibrillation HR 1.34 (95%CI 1.25-1.43) and heart failure HR 1.53 (95%CI 1.43-1.63). HRs increased further for ICS >1600 and >2400 µg daily. No increase in risk was found with ICS doses below 800 µg daily
CONCLUSION: We identified a dose-dependent risk of current high-dose ICS use on CVD onset. This highlights the importance of assessing CVD risk in patients with severe asthma. Further studies exploring this association are warranted.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | The European Respiratory Journal |
| Vol/bind | 64 |
| Udgave nummer | Suppl 68 |
| Sider (fra-til) | PA4495 |
| Antal sider | 1 |
| ISSN | 0903-1936 |
| DOI | |
| Status | Udgivet - 2024 |